Clinical Trial Update: A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating different titration schedules of ALKS 5461 in adults with Major Depressive Disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• ALKS 5461 (ALKS-5461)

Snippet

Sponsor: Alkermes, Inc. | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2019-03-27